Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations
Total Revenue Increased 34% in Second Quarter 2020 Compared to Second Quarter 2019  Despite COVID-19 Headwinds Multiple Upcoming Milestones Regarding VASCEPA ® Opportunity in United States and Internationally Management to Host Conference Call Today at 7:30 a.m.
View HTML
Toggle Summary VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD (Cardiovascular Disease) Prevention
VASCEPA showed significant reduction in coronary revascularization, including coronary stenting and cardiac bypass surgery, in prespecified and post hoc analyses of landmark REDUCE-IT study First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA
View HTML
Toggle Summary Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2020 financial results and provide an operational update
View HTML
Toggle Summary Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc.
DUBLIN, Ireland and BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today a settlement agreement with Apotex Inc. (Apotex) that resolves patent litigation that would have resulted from the previously disclosed abbreviated new drug application
View HTML
Toggle Summary VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study
Primary composite first and total major adverse cardiovascular event (MACE) reductions of 23% each shown with VASCEPA in prespecified tertiary and post hoc exploratory analyses of the subgroup of people with diabetes Key secondary composite first and total MACE reductions of 30% and 29%,
View HTML
Toggle Summary Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education
Significant Opportunity Seen as Patient Visits Resume to Emphasize VASCEPA as the First and Only Drug Approved for Its Current Cardiovascular Risk Reduction Indication DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that
View HTML
Toggle Summary Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19
DUBLIN, Ireland and BRIDGEWATER, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA®) on inflammatory biomarkers and other patient outcomes in individuals with
View HTML
Toggle Summary VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in Prespecified and Post Hoc Analyses of Landmark REDUCE-IT® Study
First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses Results of prespecified tertiary endpoint analyses consistent across different types of coronary revascularization procedures, including urgent,
View HTML
Toggle Summary Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations
Total Revenue Increased 112% to $155 Million in First Quarter 2020 Compared to Prior Year Management to Host Conference Call at 7:30 a.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., April 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for
View HTML
Toggle Summary Amarin to Report First Quarter 2020 Results and Host Conference Call on April 30, 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2020 financial results and provide an operational update
View HTML

Amarin Corporation